Edan Instruments

Edan Instruments CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Edan Instruments (300206.SZ) as of Oct 27, 2026 is 24.00 %. In the previous year, CapEx to Operating Cash Flow Ratio was 20.92 % — a change of 14.74% (higher).

CapEx/OCF

24.00 %

YoY

14.74%

Last updated:

CapEx to Operating Cash Flow Ratio of Edan Instruments is 2025 24.00 % . CapEx to Operating Cash Flow Ratio of Edan Instruments was 2024 20.92 % . It decreases by 14.74% higher compared to the previous year.

The Edan Instruments CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
44.43 CNY
Jan 1, 2019
45.89 CNY
Jan 1, 2020
7.12 CNY
Jan 1, 2021
31.00 CNY
Jan 1, 2022
12.65 CNY
Jan 1, 2023
33.19 CNY
Jan 1, 2024
20.92 CNY
Jan 1, 2025
24.00 CNY
The Edan Instruments CapEx/OCF history
YEARCapEx/OCFYoY
24.00 %+14.74%
20.92 %-36.97%
33.19 %+162.33%
12.65 %-59.19%
31.00 %+335.35%
7.12 %-84.48%
45.89 %+3.30%
44.43 %+21.70%
36.51 %-115.18%
-240.48 %-160.92%
394.74 %-70.50%
1,338.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Edan Instruments Stock analysis

What does Edan Instruments do? Edan Instruments, Inc. generates revenue through the design, manufacture, and sale of medical equipment, including maternity product series like doppler fetal heart beat monitors, ultrasonic doppler fetal heart beat monitors, fetal/maternal monitors, and maternity integrated diagnostic monitoring systems. The company also sells electrocardiograph series such as digital twelve-channel electrocardiographs, digital six-channel electrocardiographs, and electrocardiographic workstations, along with monitoring products like portable multi-variable monitors and central monitoring systems. Additionally, Edan offers spare parts and in vitro diagnostics products to support its equipment and medical services. The primary buyers of Edan's products are healthcare institutions, including hospitals and clinics, which purchase medical devices for diagnostic and monitoring purposes. These institutions rely on Edan's maternity, electrocardiograph, and monitoring systems to provide patient care. The company's in vitro diagnostics products are also sold to medical facilities for laboratory testing needs. Edan's product segments are defined by medical equipment categories: maternity, electrocardiograph, monitoring, and ultrasonic image systems. The spare parts and in vitro diagnostics businesses complement these segments by providing essential accessories and diagnostic tools. Revenue is derived from direct sales of these products to healthcare providers, with no mention of third-party distribution or additional services beyond the described offerings. Edan Instruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Edan Instruments stock

CapEx to Operating Cash Flow Ratio of Edan Instruments is 24.00 % in 2025.

CapEx to Operating Cash Flow Ratio of Edan Instruments changed from 20.92 % to 24.00 %, representing a 14.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Edan Instruments since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Edan Instruments with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Edan Instruments

All Key Metrics — Edan Instruments